{"organizations": [], "uuid": "972be27a04a84124723520127c9bbcf4ba1987fc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-accepts-new-drug-applications/brief-fda-accepts-new-drug-applications-for-mercks-doravirine-idUSASB0C00E", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Accepts New Drug Applications For Merck's Doravirine", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-08T19:32:00.000+02:00", "replies_count": 0, "uuid": "972be27a04a84124723520127c9bbcf4ba1987fc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-accepts-new-drug-applications/brief-fda-accepts-new-drug-applications-for-mercks-doravirine-idUSASB0C00E", "ord_in_thread": 0, "title": "BRIEF-FDA Accepts New Drug Applications For Merck's Doravirine", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "nnrti", "sentiment": "none"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Merck & Co Inc:\n* FDA ACCEPTS NEW DRUG APPLICATIONS FOR MERCK’S DORAVIRINE, THE COMPANY’S INVESTIGATIONAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI), FOR TREATMENT OF HIV-1 INFECTION\n* MERCK & CO INC - FDA HAS SET A TARGET ACTION DATE OF OCT. 23, 2018, FOR BOTH APPLICATIONS UNDER PRESCRIPTION DRUG USER FEE ACT\n* FDA ACCEPTS NEW DRUG APPLICATIONS FOR MERCK’S DORAVIRINE, THE COMPANY’S INVESTIGATIONAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI), FOR TREATMENT OF HIV-1 INFECTION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T19:32:00.000+02:00", "crawled": "2018-01-09T17:08:54.012+02:00", "highlightTitle": ""}